Hasiyeti Aili, Palida Palahati, Xirepanmu Zunong, Mireban Aierken, Munila Mahade*
Kashgar Prefecture second people's hospital of Xinjiang Uyghur Autonomous Region, Kashgar 844000, Kashgar Prefecture, Xinjiang Uygur Autonomous Region, China
Objective: To explore the curative effect of irinotecan combined with apatinib in the treatment of colon cancer and the analysis of prognostic factors.
Methods: The clinical data of 96 patients with colon cancer admitted to our hospital from October 2015 to October 2020 were selected for the retrospective analysis. They were divided into the treatment group (n=48, the treatment of irinotecan combined with apatinib) and the control group (n=48, calcium folinate, oxaliplatin and 5-fluorouracil) according to the double-blind method. The serum tumor marker levels were detected in the two groups by ELISA after treatment, and the Karnofsky performance status (KPS) score was used to evaluate the health status after treatment in the two groups.
Results: After treatment, the overall response rate, the KPS score and the quality of life questionnaire-core 30 (QLQ-C30) score in the treatment group were significantly higher than those in the control group (P<0.05), while the serum factor indexes and the total incidence of adverse reactions were significantly lower than those in the control group (P<0.001). The patients had a median overall survival (OS) of 31 months and a median progression-free survival (PFS) of 28 months. Univariate analysis showed that the age, TNM stage III and above, tumor diameter ≥5 cm and the preoperative CEA level >5.0 ng/mL were the influencing factors of prognosis. The results of multivariate analysis showed that the patients' age ≥60 years old, TNM stage III and above, and tumor diameter ≥5 cm were the influencing factors of prognosis for colon cancer patients (P<0.05).
Conclusion: The combination of irinotecan and apatinib is a reliable method to improve the quality of life and reduce the tumor marker levels in patients with colon cancer, so that it can be recommended for the treatment of colon cancer.
Irinotecan, apatinib, colon cancer, curative effect, prognostic factors.